Skip Nav Destination
Issues
1 March 2014
-
Cover Image
Cover Image
STAT3 and NF-κB signaling pathways are often simultaneously activated in neoplastic cells and play important roles in tumorigenesis and drug sensitivity. TPCA-1, a previously found antagonist of IKKs, blocks STAT3 anchoring to upstream tyrosine kinase and inhibits STAT3 activation induced by cytokines and c-Src. Molecular modeling indicates that TPCA-1 is well docked into SH2 domain of STAT3 and formed hydrogen bond with Glu594. As a direct inhibitor of STAT3 and IKKs, TPCA-1 inhibits growth of non–small cell lung cancer (NSCLC) with EGFR mutation and potentiates the antitumor effect of gefitinib. For details, see article by Nan and colleagues on page 617. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Hypothesis/Commentary
Small Molecule Therapeutics
A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo
Fardokht Abulwerdi; Chenzhong Liao; Meilan Liu; Asfar S. Azmi; Amro Aboukameel; Ahmed S.A. Mady; Thippeswamy Gulappa; Tomasz Cierpicki; Scott Owens; Tao Zhang; Duxin Sun; Jeanne A. Stuckey; Ramzi M. Mohammad; Zaneta Nikolovska-Coleska
Author Choice
Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer
Cleo E. Rolle; Rajani Kanteti; Mosmi Surati; Suvobroto Nandi; Immanuel Dhanasingh; Soheil Yala; Maria Tretiakova; Qudsia Arif; Todd Hembrough; Toni M. Brand; Deric L. Wheeler; Aliya N. Husain; Everett E. Vokes; Ajit Bharti; Ravi Salgia
The Fatty Acid Synthase Inhibitor Orlistat Reduces the Growth and Metastasis of Orthotopic Tongue Oral Squamous Cell Carcinomas
Michelle Agostini; Luciana Y. Almeida; Débora C. Bastos; Rose M. Ortega; Fernanda S. Moreira; Fabiana Seguin; Karina G. Zecchin; Helena F. Raposo; Helena C.F. Oliveira; Nivea D. Amoêdo; Tuula Salo; Ricardo D. Coletta; Edgard Graner
Large Molecule Therapeutics
Cancer Biology and Signal Transduction
Tools and Technologies
Author Choice
Cancer-Associated CD43 Glycoforms as Target of Immunotherapy
Franca Maria Tuccillo; Camillo Palmieri; Giuseppe Fiume; Annamaria de Laurentiis; Marco Schiavone; Cristina Falcone; Enrico Iaccino; Ricciarda Galandrini; Cristina Capuano; Angela Santoni; Francesco Paolo D'Armiento; Claudio Arra; Antonio Barbieri; Fabrizio Dal Piaz; David Venzon; Patrizia Bonelli; Franco Maria Buonaguro; Iris Scala; Massimo Mallardo; Ileana Quinto; Giuseppe Scala
Letters to the Editor
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.